Economia

Evolent Health, Inc (EVH) Receives Outperform Rating from Cowen and Company

Evolent Health, Inc (EVH) Receives Outperform Rating from Cowen and Company

The most optimistic analyst sees the stock reaching $35 while the most conventional has $27 target price. Leerink Swann also issued estimates for Evolent Health's Q4 2017 earnings at ($0.05) EPS, FY2017 earnings at ($0.53) EPS and FY2018 earnings at $0.10 EPS.

Comparatively, Evolent Health, Inc. posted earnings of $0 per share in the same quarter past year.

As of the latest earnings report the EPS was $-1.23 and is estimated to be $-0.41 for the current year with 65,822,000 shares now outstanding. Evolent Health had a negative return on equity of 6.44% and a negative net margin of 17.57%. The high and low revenue estimates for the current quarter are $106.8 Million and $103.42 Million, respectively. During the same quarter in the prior year, the company earned ($0.20) earnings per share. The company reported revenue of $0 in the same period a year ago. COPYRIGHT VIOLATION WARNING: This story was published by Transcript Daily and is the property of of Transcript Daily. If you are reading this piece on another site, it was illegally stolen and republished in violation of USA and worldwide trademark & copyright laws. The legal version of this report can be accessed at https://www.chaffeybreeze.com/2017/08/11/evolent-health-nyseevh-earns-daily-news-impact-rating-of-0-15-updated.html. Evolent Health, Inc.'s average EBITDA per Share Growth Rate was 0 percent during the past 12 months.

Taking a glance at where the stock might be directed in the future, on a consensus basis, the sell-side has a 52 week price target of $30.36 on the stock, this valuation is based on 11 number of opinions.

Evolent Health, Inc (NYSE:EVH) was downgraded by research analysts at BidaskClub from a "hold" rating to a "sell" rating in a research report issued on Saturday. Jefferies Group LLC restated a "buy" rating and set a $28.00 price objective on shares of Evolent Health in a research report on Thursday, April 13th. Robert W. Baird set a $35.00 price objective on Evolent Health and gave the company a "buy" rating in a research report on Tuesday. 1 is equivalent to a buy rating, 3 a hold rating, and 5 a sell rating.

Evolent Health Inc Class A Com (NYSE:EVH) has grabbed attention from the analysts, when it saw a value decrease of -8.56% or -1.7 points in the last trading session to close at $18.15. A P/B ratio of less than 1.0 can indicate that a stock is undervalued, while a ratio of greater than 1.0 may indicate that a stock is overvalued. Relative Strength Index (RSI-14) for Evolent Health, Inc.

Earnings per share (EPS) is the portion of a company's profit allocated to each outstanding share of common stock. Its share price has decline -26.67% in three months and is down -24.84% for the last five trades. Following the transaction, the insider now directly owns 6,434,283 shares in the company, valued at $156,353,076.90. The stock was sold at an average price of $23.73, for a total transaction of $386,799.00. Following the completion of the transaction, the chief operating officer now owns 341,092 shares in the company, valued at $8,523,889.08. Nicholas Mcgrane, CFO disclosed the sale of 10,495 shares of (EVH). In the last 90 days, insiders have sold 10,153,967 shares of company stock valued at $253,648,377.

Several hedge funds have recently made changes to their positions in EVH. US Bancorp DE raised its position in Evolent Health by 0.3% in the first quarter. FMR LLC now owns 9,864,775 shares of the technology company's stock valued at $250,073,000 after buying an additional 5,333,252 shares in the last quarter. JPMorgan Chase & Co. raised its stake in Evolent Health by 123.0% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,744 shares of the technology company's stock valued at $150,000 after buying an additional 5,000 shares in the last quarter. Pennant Capital Management LLC increased its position in Evolent Health by 2.9% in the first quarter. Vanguard Group Inc. now owns 3,769,869 shares of the technology company's stock worth $95,566,000 after buying an additional 1,237,941 shares in the last quarter. Wigginton now owns $319,583 of stock per an SEC filing yesterday.

Analysts' mean recommendation for Evolent Health, Inc. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. (NASDAQ:TRUE) established that the company was able to keep return on investment at -14.05 in the trailing twelve month while Reuters data showed that industry's average stands at 17.89 and sector's optimum level is 12.55.